The world’s largest custodian bank now holds a total of 16,840,686 securities in the Australian oncology-focused biotech company.
Kazia Therapeutics chief executive officer James Garner said the superior results from the ongoing study of GDC-0084 in newly-diagnosed glioblastoma patients was an important milestone for the company.
He added the current, second stage of the two-part study (which began in September) will transition into observing more patients, with higher doses of the drug.
READ: Kazia Therapeautics’ ongoing study confirms higher drug tolerability in newly-diagnosed glioblastoma patients
Garner continued: “One of the exciting things about our drug GDC-0084 is that its designed to cross the blood-brain barrier.
“We are focusing on newly-diagnosed patients in earlier stages of the disease and we think we can offer a much bigger benefit there.”
The company confirmed a higher maximum tolerated dose (MTD) of 60 milligrams in new safety data from its ongoing phase-IIa clinical study earlier this week.